Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473314 | 1.00 | HTR2A (0.35) | HTR2AHTR2CHTR2BRIPK1NR1H2 | |
| SCHEMBL23491497 | 0.90 | HTR2A (0.34) | HTR2AHTR2CHTR2BRIPK1NR1H2 | |
| SCHEMBL22473529 | 0.85 | SCN9A (0.38) | NR1H2NR1H3SCN9A | |
| SCHEMBL22473533 | 0.85 | SCN9A (0.38) | NR1H2NR1H3SCN9A | |
| SCHEMBL22473316 | 0.85 | SCN9A (0.38) | NR1H2NR1H3SCN9A | |
| SCHEMBL22473175 | 0.80 | RIPK1 (0.40) | RIPK1NR1H2NR1H3SCN9A | |
| SCHEMBL22473186 | 0.80 | RIPK1 (0.40) | RIPK1NR1H2NR1H3SCN9A | |
| SCHEMBL22473188 | 0.80 | RIPK1 (0.40) | RIPK1NR1H2NR1H3SCN9A | |
| SCHEMBL23491495 | 0.80 | GRIA4 (0.33) | HTR2AHTR2CHTR2BRIPK1KDM1A | |
| SCHEMBL22473243 | 0.74 | OPRM1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | HTR2A 2503/4885HTR2C 3643/4885HTR2B 671/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | HTR2A 2503/4885HTR2C 3643/4885HTR2B 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.